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Abstract 
Background: Infectious diseases continue to play an important role for disease perception, health-
economic considerations and public health in Germany. In recent years, infectious diseases have been 
linked to the development of non-communicable diseases. Analyses of the German National Cohort 
(GNC) may provide deeper insights into this issue and pave the way for new targeted approaches in 
disease prevention. 
Objectives: The aim is to describe the tools used to assess infectious diseases and to present initial 
data on infectious disease frequencies. Also, to relate the GNC assessment tools to data collection 
methods in other studies in Germany. 
Methods: As part of the baseline examination, questions regarding infectious diseases were 
administered using both an interview and a self-administered touchscreen questionnaire. Data from 
the initial 101,787 GNC participants were analysed. 
Results: In the interview, 0.2% (HIV/AIDS) to 8.6% (shingles) of respondents reported ever having a 
medical diagnosis of shingles, postherpetic neuralgia (in case shingles were reported), hepatitis B/C, 
HIV/AIDS, and tuberculosis, and sepsis if treated in hospital. In the questionnaire, 12% (cystitis) to 81% 
(upper respiratory tract infections) of respondents reported having experienced at least one 
occurrence of upper or lower respiratory tract infections, gastrointestinal infections, cystitis, or fever 
within the past 12 months.  
Outlook: Further cross-sectional analyses of data and tools presented here - for example on 
determinants of susceptibility to self-reported infections - can be anticipated from the year 2021 
onward. Beyond that, more extensive research into infectious disease epidemiology will be possible, 
particularly once analyses of GNC biological materials have been performed. 
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Introduction 
Infectious diseases continue to play an important role for the subjective disease perception, health 
economic considerations and public health in Germany, even if they are no longer the leading causes 
for morbidity and mortality. They contribute considerably to the loss of healthy years of life [1]. Due 
to their contagiousness and preventability through hygiene measures and vaccination, communicable 
diseases are important for public health and subject to public debate. In recent years, infectious 
diseases have been associated with the development of non-communicable diseases in a complex 
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interplay with the immune system, psyche, microbiome, genetics and lifestyle factors [2, 3]. In 
addition, the impact of certain infections on carcinogenesis like hepatitis B virus infection (liver cell 
carcinoma) or human papillomavirus infection (cervical carcinoma) is also known [4]. Data and 
biosamples of the German National Cohort (GNC) may provide further insights in this regard, and pave 
the way for more targeted approaches to disease prevention. Especially, the use of several omics 
technologies in multi-omics analyses of different biosamples will play a role. This approach aims, for 
example, at the joint analysis of genetic data together with data from comprehensive transcriptome, 
protein or microbiome analyses. In combination with self-reported infection events, a paradigm shift 
towards personalised prevention and medicine can be supported.  
Central assessment tools in the GNC are the computer-assisted interview ('face-to-face') and the self-
administered questionnaire that is filled in independently at desktop computers (touchscreen module) 
by the participants in the study centre [5]. For both tools, the questions on infectious diseases were 
compiled from 2009 onwards by experts in the area of infections and the immune system. Included in 
the interview are questions referring to the entire life course and to infectious diseases that may have 
a chronic progression. These particular questions are asked in a specific way to rule out self-diagnosis. 
Transient infections are queried in the touchscreen module. Such infections that occur mostly only 
temporary like acute respiratory infections are also suitable for self-diagnosis. The self-administered 
questionnaires of the touchscreen module were evaluated in both GNC pretests between 2011 and 
2013. The results indicate the suitability of the infection-specific questionnaire to assess the targeted 
diseases and showed acceptable reliability [6, 7]. 
The aim of this paper is to describe the GNC tools to assess self-reported infectious diseases. 
Additionally, first data on disease frequencies are reported, and the assessment tools are put into 
context with tools used in other studies or in the German notification system, which is based on the 
Infection Protection Act (German abbreviation: IfSG). In this way, GNC assessment tools are positioned 
within the existing research landscape. 
 
Methods 
The presented data originate from the first 101,791 participants, examined in 18 GNC study centres 
between 14 March 2014 and 17 March 2017. The GNC is a population-based German cohort study with 
the aim of including 200,000 participants between the ages of 20 to 69 years. The baseline recruitment 
was conducted in 2014-2019, while the follow-up period is scheduled for 20-30 years [8]. The questions 
on infectious diseases were included in the so-called level-1-examination and were intended for all 
participants. The GNC study protocol has been reviewed by the respective ethics committees and data 
protection officers. All participants provided signed informed consent before taking part in the study 
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[4]. The data presented in this publication (age, gender) are not quality-assured. Also, the data on 
diagnoses are not validated based on medical data. The infectious disease questions considered in 
both the interview and the self-administered questionnaire, including the respective response options, 
are presented in Table 1. The interview queries medical diagnoses of infections, or, in the case of 
sepsis, hospitalisation. In contrast, all responses to the self-administered questionnaire rely on self-
diagnosis. In this publication, the interview questions were analysed only concerning the age of the 
participant at the time he or she visited the study centre. Further analyses, such as the consideration 
of age at diagnosis, are reserved for future research. Therefore, the age-stratified figures reflect the 
frequencies at the age at examination. Within the touchscreen module, the response options for the 
occurrence of the infectious diseases have been aggregated, i.e. the presence of at least one disease/ 
symptom is reported. For both instruments, the response options 'no answer', 'do not know' and 
missing values have been excluded for the calculation of proportions. These answers are reported 
separately. Some participants exceeded the maximum recruitment age of 69 years at their first site 
visit. Therefore, the age group of >= 70 years has been specified in age-stratified analyses. 
Furthermore, four participants have been excluded due to implausible or missing reports on age. For 
herpes zoster and postherpetic neuralgia, cases have been omitted from the analyses if the age at 
diagnosis was below 21 because such cases are considered medically implausible. 
All analyses have been conducted with R, Version 3.6.0, including the package 'tidyverse'. 
 
Results 
In total, 101,787 participants were included in the analysis. The median age site visit was 53 years 
(interquartile range 45-62 years); 53.6% (54,526/101,787) were female. There were 2,971 (2.9%) 
participants in the age group of 70 years and older. In the interview, the occurrence of herpes zoster, 
postherpetic neuralgia, hepatitis B and C, HIV/ AIDS, tuberculosis was queried in terms of a medical 
diagnosis. For sepsis, hospitalisation was queried. Between 0.2% (HIV/ AIDS) and 8.6% (herpes zoster) 
of the participants reported the diagnosis of the respective infectious disease during their life span by 
a medical doctor (Table 2). In the touchscreen module, infection episodes were inquired concerning 
the past 12 months for lower respiratory tract infections (LRTI), upper respiratory tract infections 
(URTI), bladder infections, gastrointestinal infections or fever (>38°C). For these infections, at least one 
episode was reported from 12.2% (bladder infection) up to 81.2% (URTI) of responders. (Table 2). Here, 
URTI were reported most frequently, followed by gastrointestinal infections, fever and lower 
respiratory tract infections. Figures 1 to 3 present the proportions of participants, stratified by age and 
sex, which reported the respective disease or symptom within the life course (interview) or within the 
past 12 months (touchscreen module). Hepatitis C and HIV/ AIDS were the least frequently reported 
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diseases and are additionally presented in Figure 2 with a modified scale for better presentability. 
HIV/AIDS were mainly reported by men, and bladder infections mainly by women. Considering data 
quality, the proportion of data that can be analysed from the interview is very high (97.1% and more, 
Table 2), while this proportion is lower for the questions of the touchscreen module (90.0-91.2%, Table 
2). 
 
Discussion 
This publication is the first to present results of the GNC regarding infectious diseases or their 
symptoms, respectively. Due to the long follow-up-period, the GNC has immense potential for research 
on risk factors or predictors of infectious diseases and their effects. The storage of biosamples allows 
future research on biomarkers associated with increased infection risk or on biological mechanisms in 
the context of infections and non-communicable diseases [8]. 
Standardised indicators of disease frequencies in terms of prevalences or incidences are not directly 
to be derived from the presented numbers. The calculation of these numbers is planned for future 
disease-specific research in order to characterise the GNC accordingly. Here, it should be noted that 
only survivors report the diseases, therefore, the numbers might be underestimated. Hence, GNC 
disease frequencies in the framework of existing studies or the German notification system will be 
discussed in future disease-specific publications. In contrast, this publication serves the purpose to put 
the questionnaires used into the context of the research landscape and, therefore, to show the 
potential of the GNC. 
The age-specific frequencies of the infectious diseases ascertained in the GNC and presented here can 
only be compared to a limited degree to notification data, health insurance data or studies with a focus 
on prevalence or incidence assessment. The reason being that the frequencies presented in Figure 1 
and 2 do not consider the age at diagnosis, but the question if the respective disease has ever been 
diagnosed during the life course. Thus, the figures only show the age at disease assessment on site. 
Furthermore, it is known that it is a challenge to recall medical events correctly, especially if the events 
lie further back in time [9, 10]. The diseases and symptoms queried in the touchscreen module (Figure 
3) probably provide a more precise representation of the age at diagnosis as the questionnaire queries 
occurrences within the past 12 months of the time of site visit. In general, validation of the self-reports 
is reasonable, and can be at least be partially realised by health insurance data in the future. Here, it 
should be kept in mind that not all symptomatic patients necessarily visit a doctor’s practice. 
The interview data have excellent quality in terms of valid answers, but the touchscreen module data 
score considerably less well (Table 2). It cannot be determined if a missing answer equals the absence 
of the disease, and, thus, results may be biased. The frequencies presented in Table 2 refer to all 
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participants with a valid answer (without missing values, 'no answer' and 'do not know'). Consequently, 
the calculated results may be biased. This issue could be addressed in future analyses with appropriate 
methods, e.g. multiple imputation [11]. 
In the following, all reported infectious diseases or symptoms are put into the context of the research 
landscape. Additionally, an outlook on research questions will be given that can be answered with GNC 
data in the future. 
 
Tuberculosis 
In Germany, every case of tuberculosis (TB) is required by law (IfSG) to be reported to health 
authorities. The data are published yearly by the Robert Koch-Institute (RKI) in their disease-specific 
report [12]. The German notification system meets international quality standards [13]. Nevertheless, 
gaps in notifications are still possible. These might occur in vulnerable populations or only clinically 
diagnosed forms of TB without microbiologic verification. Further research data on TB are included in 
health insurance data. Data collections on specific populations who underwent active surveillance 
either for active or latent TB, e.g. for occupational reasons [14], or because of serial X-ray examinations 
[15], allow a different type of (historical) comparison [16]. Apart from the mentioned limitations for 
the GNC self-reports, there is the challenge that latent TB may be falsely reported as tuberculosis. 
Positive tests (e.g. tuberculin skin test) hint at latent TB, but unlike active tuberculosis, the condition 
is asymptomatic, and the microbiological detection of M. tuberculosis complex remains negative. This 
may result in an overestimation of the frequencies reported in the GNC. In our view, potential uses for 
the GNC data especially arise if the diagnosis for active or latent tuberculosis were confirmed, e.g. by 
information from biomaterials. In this case, crucial issues concerning disease progression after TB and 
possible consequences (e.g. restriction of lung function) can be investigated. This would exceed the 
follow-up-period of most of the existing other international cohort studies [17, 18]. 
 
Herpes zoster and postherpetic neuralgia 
Despite the high disease burden of herpes zoster [19], there is no obligation to report the disease to 
authorities in Germany because of its low contagiousness. Therefore, studies concerned with the 
epidemiology of the disease are mostly based on secondary data [20, 21]. These studies were able to 
detect and quantify previously unknown cardiac and cerebrovascular consequences of a varicella-
zoster virus (VZV) reactivation.  
For herpes zoster and post-zoster neuralgia, an assessment of the validity of GNC pretest data has 
been performed. Presumably, earlier herpes zoster episodes were less likely to be reported than more 
recent episodes [24]. As already mentioned earlier, this embodies an important limitation of the self-
reported infectious diseases in the GNC. 
8 
 
From an epidemiological point of view, GNC baseline and follow-up examinations are conducted within 
an interesting time period, since in Germany, the varicella (chickenpox) vaccination has been 
recommended by authorities since 2004 [25] and the herpes zoster vaccination since 2019 [26]. In 
contrast to studies based solely on secondary data, the longitudinal design of the GNC with repeated 
collection of biosamples and integration of vaccination card data allows research on risk factors and 
biomarkers for VZV-reactivation and possibly provides insight into molecular causes for vaccination 
failure. The results could be used for the development of personalised vaccination strategies. 
 
HIV/ AIDS 
In Germany, various tools are available to estimate the disease burden of HIV/ AIDS. A case register 
has been available since 1982, based on voluntary and anonymous reports of patients by physicians 
[27]. Since 1987, laboratories have been required to anonymously notify positive HIV-tests (currently 
§ 7 par. 3 IfSG). Furthermore, reports on HIV frequencies from routine tests of all blood donations have 
been available [27]. From these data sources and the cause-of-death statistics of the statistical offices 
of the federal states as well as the sales data on antiretroviral therapy from pharmacy accounting 
centres, the RKI estimates incident HIV infections [28]. Additionally, multiple patient registers or 
cohorts exist, e.g. the HIV-1 seroconverter-study managed by the RKI since 1997 [29] or registries with 
clinical patient data ([30], www.tp-hiv.de). The 'Translational Platform HIV' (TP-HIV) has an integrated 
biobank and, therefore, allows molecular-genetic transmission investigations [31, 32]. Due to the low 
number of cases, it is difficult to answer specific research questions regarding HIV within the GNC; 
rather, information on HIV-infection may be used as exclusion criteria or confounder for immunological 
and infectiological GNC analyses. 
 
Hepatitis B and C virus infection  
In terms of hepatitis B and C virus infections (HBV/ HBC), the long latency between the infection and 
clinical disease as well as the often asymptomatic nature of the condition challenge epidemiological 
research. This becomes apparent in the cause-of-death statistics and the statistics of notifiable 
infectious diseases. According to updated surveillance case definitions, acute HBV cases are registered 
independently of stage and clinical presentation [33]. Thereby, asymptomatic cases can be reported, 
which addresses the underestimation of HBV in notifiable disease records. Additionally, blood donors 
are tested for both viruses [34]. The screening of pregnant women generates additional information 
regarding chronic HBV-infection [35] as do studies among high-risk populations [36] and individuals 
infected with HIV [37]. As for other infections, secondary data from health insurances can be analysed 
scientifically. However, these are restricted to individuals with insurance and focus on treatment 
parameters (e.g. [38]). Also, patient registries and studies comprise specific data, e.g. on disease 
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progression (www.deutsche-leberstiftung.de). Similar to HIV/AIDS, data on hepatitis in the GNC will 
mainly play a role as exclusion criteria because participants are rarely affected. On the other hand, 
long-term follow-up data from the GNC can investigate consequences of chronic viral hepatitis 
infection. Given the existence of serological vaccine markers for HBV, the collection of vaccination data 
within the GNC provides options for a comparative analysis of self-reported and serologically 
determined HBV immunity. Also, explorative investigations on proportion and predictors of possible 
HBV vaccine-non-responders can be conducted. 
 
Infections of the upper respiratory tract 
Infections of the upper respiratory tract are among the most frequent infectious diseases [39]. This is 
reflected in the frequencies obtained from the touchscreen module (Table 2). Moreover, e.g. influenza 
caused 33,116 disability-adjusted life years (DALYs) in 2005-2007 in Germany [40]. GNC data and if 
applicable, complemented by health insurance data, can provide insights into susceptibility to 
respiratory infections. This enables the investigation of a spectrum of immune-mediated phenotypes 
and, therefore, represents important participant-specific information for longitudinal questions. The 
construct ‘infection susceptibility’ can be integrated into these research questions as a global measure 
considering all information concerning infections and future biosample analysis (e.g. serostatus). 
Furthermore, the data analysis regarding URTI may contribute to confirm or extend the results of 
specialised local population studies (AWIS: [3, 41], LIFE-Adult: [42]) or studies focusing only on acute 
respiratory infections like GrippeWeb [43].  
 
Infections of the lower respiratory tract 
In Germany, pneumonia causes over 250,000 hospitalisations each year with a case fatality rate of 
approximately 13% [44]. Globally, infections of the lower respiratory tract (LRTI) are responsible for 
approximately 103 million DALYs [45]. With GNC data, existing studies on pneumonia from the clinical 
perspective ((CAPNETZ [46], PROGRESS [47]) can be expanded by the analysis of molecular factors and 
lifestyle data, and put on a wider data basis. Furthermore, the longitudinal design allows the 
assessment of long-term consequences of respiratory infections such as cardiovascular events [48]. 
Within future publications, the GNC data will be evaluated: It is conceivable, for instance, that 
respiratory diseases, such as asthma or chronic obstructive pulmonary disease (COPD), are mistaken 
for LRTI, which would lead to an overestimation of cases. The comprehensive database of the GNC, 
including information on medication intake, allows for a more differentiated consideration in the 
future. 
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Gastrointestinal infections 
Acute gastrointestinal infections lead to 63.2 million missed working days due to illness [49]. In 
Germany, gastrointestinal illnesses are among the infectious diseases most frequently reported to the 
Robert Koch-Institute, which is particularly the case for infections caused by norovirus, rotavirus, 
campylobacter and salmonella [50]. Mild or moderate gastrointestinal tract infections are often not 
reported, especially among adults [51]. The results of international studies confirm this [52-55]. 
Depending on the study, only 20 to 40% of the diseased consulted a doctor; stool samples with 
pathogen diagnostics were only available for a fraction of these patients. For Germany, only a few 
epidemiological studies on gastrointestinal infections are available outside of outbreak investigations. 
In 2009, Wilking et al. surveyed more than 20,000 people once concerning acute gastrointestinal 
illnesses and their symptoms within the past four weeks [49]. In 2009-2010, a pilot project of the 
National Reference Network for Enteral Infections (NEI) analysed 185 stool samples of ambulant and 
hospitalised diarrhoea patients for gastrointestinal pathogens. Only 51% of the samples contained 
potential enteropathogens. This study aimed to establish a uniform approach for the systematic 
acquisition of relevant pathogens from stool [56]. This procedure should then be applied in 
epidemiological studies of NEI. In the context of the GNC, the enquiry of diarrhoeal diseases enables 
to approximately define the construct ‘infection susceptibility’ together with other queried infections 
and put into relation with other diseases addressed (longitudinally) in the GNC. Add-on studies, so 
called level 3 studies, within the GNC would enable to investigate pathogen-specific research questions 
by capturing incident events promptly. For instance, this would be feasible within the scope of the 
'Integrated DZIF Infection Cohort within the German National Cohort (ZIFCO; www.info-pia.de). 
 
Urinary tract infections 
In Germany, there are no comparable studies with similar data collection on urinary tract infections 
(UTI). Following IfSG, there is no obligation to notify. The former Barmer GEK health insurance 
determined the UTI prevalence of the insured aged 12 and over for 2013 [57]. However, this study 
used secondary data which only capture cases in which a doctor has been consulted. The European 
ARESC-study with study centres in Germany analysed the pathogen spectrum for the assessment of 
the resistance situation. The goal was to evaluate the recommendations regarding uncomplicated 
cystitis [58]. Hence, GNC data can fill in a gap. Apart from that, the data can be considered for the 
construct ‘infection susceptibility’ (see above section on URTI). Additionally, self-reports on UTI from 
international studies mostly originate from female study populations [59, 60]. The self-reports from 
male GNC participants may add to this data to gain a broader insight into the epidemiology of transient 
infections. Finally, long-term effects of frequent UTI in women can be investigated, e.g. unspecific 
consequences such as shortened life expectancy. 
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Fever 
Fever is a symptom of infection. It is commonly ascertained in studies as a symptom, e.g. of respiratory 
tract infection to differentiate between influenza-like illness (ILI) and common cold [61]. This is 
especially true for studies that complement the notification system by supplementary surveillance 
such as GrippeWeb [43]. Clinical studies on LRTI or sepsis also collect data on fever and, in some 
instances, also hypothermia [47]. However, temperature thresholds often differ between studies, 
which in turn limits cross-cohort evaluations (e.g. LIFE-Adult: >38.5°C in case of infection [42]; 
PROGRESS: >=38.3°C rectally or >=37.8°C orally [47]; GNC separate question: >38°C). The GNC data can 
be incorporated into the construct ‘infection susceptibility’ in future analyses and taken into account 
in molecular investigations of the immune system. 
 
Sepsis 
Sepsis is a common complication of various diseases and especially occurs in hospitals and intensive 
care. The incidence is approximately 110 cases per 100,000 inhabitants per year and is associated with 
a high case fatality rate [62]. In sepsis, the initially targeted immune response of the body systemically 
expands, which can lead to considerable organ damage and death. Therefore, sepsis is an important 
medical research area. Large cohort studies like the GNC, with information on risk factors, molecular 
data and health insurance data can assist research on sepsis together with data from clinical cohorts 
(AlertsNet [63], SepNet study group (www.sepsis-stiftung.eu/sepnet/), PROGRESS 
(www.capnetz.de/html/progress/project), [47, 64]), population-based cohorts (LIFE-Adult [42]) and 
additional health insurance data. Here, the GNC also provides data on participants who have overcome 
sepsis and are healthy for study participation. 
 
In summary, it can be stated that on all infectious diseases queried in the GNC numerous and very 
diverse research questions can be investigated in the future. Thereby, the GNC complements the 
existing research landscape in a variety of ways.  
 
Outlook 
Based on a cross-sectional design, publications on results from the GNC in the area of infection 
research can be expected from 2021 onwards, e.g. on determinants of susceptibility to certain self-
reported infections. In particular, it will be possible to examine the distribution of infectious diseases 
by social class. Further research in the field of infectious disease epidemiology will be feasible after 
GNC biosamples have been analysed.  
Separately financed serological determinations of antibodies against the causal pathogen of Lyme 
disease and analyses of the stool or nasal microbiome up to high-dimensional multi-omics analyses are 
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also conceivable. Infection-specific subcohorts with timely data and symptomatic biosample collection 
concerning acute infections as well as the collection of viable blood cells for characterisations of the 
immune system (www.info-pia.de) require additional funding. These types of investigations have not 
been conducted within the GNC so far. Future research in the area of infectious disease epidemiology 
will, therefore, focus on these additional projects and analyses. 
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Table 1 Questions and possible answers of GNC survey tools 
Question (Infectious-)Disease Possible answers 
Interview 
Have you ever been 
medically diagnosed with 
one of the following 
infectious diseases? 
 
 
Tuberculosis  Yes 
 No 
 Prefer not to 
answer 
 Don’t know 
Herpes zoster 
Postherpetic neuralgia (if herpes zoster was 
reported) 
HIV/ AIDS 
Hepatitis B 
Hepatitis C 
Have you ever received 
inpatient treatment in a 
hospital for blood poisoning, 
also known as sepsis? 
 
 Yes 
 No 
 Prefer not to 
answer 
 Don’t know 
Infectious disease questions in the touchscreen-module 
In the past 12 months, how 
often have you had… 
...an infection of the upper respiratory tract (e.g. a 
cold or infections of the sinus cavities, tonsils, 
middle ear, throat, voice box)? 
 Never 
 1 time 
 2 times 
 3- to 4 times 
 5- to 6 times 
 More than 6 
times  
 Prefer not to 
answer 
 Don’t know 
... an infection of the lower respiratory tract (e.g. 
bronchitis or lung inflammation)? 
...a gastrointestinal infection with diarrhoea 
(diarrhoea is defined as at least three liquid/ 
mushy bowel movements within 24 hours)? 
...a bladder infection? 
...fever (>38°C)? 
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Table 2 Frequencies of self-reported infections in the GNC interview und touchscreen 
 Reporting of the 
disease: n (%) 
Considered answers: 
n 
Missing values, 
‘Prefer not to 
answer’, ‘Don’t 
know’: n 
Interview (Self-reports for medical diagnosis in the course of life) 
 
Tuberculosis 1,423 (1.4) 101,453 334 
HIV/ AIDS 156 (0.2) 
 
101,652 
 
135 
 
Hepatitis B 1,615 (1.6) 
 
100,499 
 
1,288 
 
Hepatitis C 557 (0.6) 
 
100,710 
 
1,077 
 
Herpes zoster 8,518 (8.6) 
 
98,793 
 
345 
 
Postherpetic neuralgia 587 (7) 
 
8,418 
 
100 
 
Sepsis as a reason for 
hospitalisation 
2,434 (2.4) 
 
101,366 
 
421 
 
 
Infectious disease questions in the touchscreen-module (self-reports considering the past 12 months) 
 
At least one infection of the 
upper respiratory tract (URTI) 
75,380 (81.2) 92,853 
 
8,934 
 
At least one infection of the 
lower respiratory tract (LRTI) 
19,892 (21.7) 
 
91,829 
 
9,958 
 
At least one gastrointestinal 
infection 
35,111 (38.0) 
 
92,293 
 
9,494 
 
At least one bladder infection 11,227 (12.2) 
 
92,232 
 
9,555 
 
At least one occurrence of fever 
(> 38°C) 
23,250 (25.4) 
 
91,609 
 
10,178 
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Figure 1: Age- and gender-specific frequencies of infectious diseases (%) ever medically diagnosed, 
from the interview. The age data are aggregated into 10-year groups. 
 
 
 
 
 
 
 
 
22 
 
Figure 2: Part of figure 1 with modified scale for better representation. Age- and gender-specific 
frequencies of infections (%) ever medically diagnosed with hepatitis C or HIV/ AIDS, from the 
interview. The age data are aggregated into 10-year groups. 
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Figure 3: Age- and gender-specific frequencies (%) of the infectious diseases or symptoms within 
the past 12 months, from the touchscreen module. The age data are aggregated into 10-year 
groups. 
 
 
 
